Benzinga | Jan 28, 2021 04:18PM EST

ResMed Q2 EPS $1.41 Beats $1.26 Estimate, Sales $800.00M Beat $783.18M Estimate

ResMed (NYSE:RMD) reported quarterly earnings of $1.41 per share which beat the analyst consensus estimate of $1.26 by 11.9 percent. This is a 16.53 percent increase over earnings of $1.21 per share from the same period last year. The company reported quarterly sales of $800.00 million which beat the analyst consensus estimate of $783.18 million by 2.15 percent. This is a 8.67 percent increase over sales of $736.16 million the same period last year.